C3 and amyotrophic lateral sclerosis: All of these biomarkers are up-regulated in the plasma of ALS patients, except the peptide derived from the C-terminal part of the complement C3f fragment (C3f), a peptide liberated during the degradation of complement C3d fragment (C3b).